This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
Singapore has approved the use of the Nuvaxovid vaccine by Novavax in its National Vaccination Programme for individuals aged 18 years and above for both the primary and booster vaccination shot.
An illustration picture shows vials with COVID-19 Vaccine stickers attached and syringes with the logo of U.S. biotech company Novavax, on Nov. 17, 2020. Justin Tallis/AFP via Getty Images
Singapore has approved the use of the Nuvaxovid vaccine by Novavax in its National Vaccination Programme for individuals aged 18 years and above for both the primary and booster vaccination shot.
This follows the Health Sciences Authority’s (HSA) interim authorization of the vaccine under the Pandemic Special Access route.
